Effects of Pharmacologic Treatment for Neonatal Abstinence Syndrome on DNA Methylation and Neurobehavior: A Prospective Cohort Study.
Objective: To determine whether pharmacologic treatment for neonatal abstinence syndrome (NAS) is associated with changes in DNA methylation (DNAm) of the mu-opioid receptor gene (OPRM1) and improvements in neonatal neurobehavior.Study Design: Buccal swabs were collected from 37 neonates before and...
| Publicado en: | Journal of Pediatrics Vol. 243; pp. 21 - 27 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | research Journal Article |
| Publicado: |
Elsevier B.V.
Apr2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=155886928&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 155886928 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00223476 04M jtl: Journal of Pediatrics issn: 00223476 maglogo: N pubinfo: dt: Apr2022 vid: 243 pid: 467 pub: Elsevier B.V. place: New York, New York artinfo: ui: 155886928 155886928 NLM34971656 155886928 10.1016/j.jpeds.2021.12.057 NLM34971656 155886928 ppf: 21 ppct: 6 formats: tig: atl: Effects of Pharmacologic Treatment for Neonatal Abstinence Syndrome on DNA Methylation and Neurobehavior: A Prospective Cohort Study. aug: au: Camerota, Marie Davis, Jonathan M. Dansereau, Lynne M. Oliveira, Erica L. Padbury, James F. Lester, Barry M. affil: Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI sug: subj: Neonatal Abstinence Syndrome Diagnosis Neonatal Abstinence Syndrome Neonatal Abstinence Syndrome Drug Therapy Infant, Newborn DNA Methylation Prospective Studies Muscle Hypertonia Drug Therapy Morphine Therapeutic Use Muscle Hypertonia Funding Source Infant, Newborn: birth-1 month ab: Objective: To determine whether pharmacologic treatment for neonatal abstinence syndrome (NAS) is associated with changes in DNA methylation (DNAm) of the mu-opioid receptor gene (OPRM1) and improvements in neonatal neurobehavior.Study Design: Buccal swabs were collected from 37 neonates before and after morphine treatment for NAS. Genomic DNA was extracted, and DNAm was examined at 4 cytosine-phosphate-guanine (CpG) sites within the OPRM1 gene. Assessment with the NICU Network Neurobehavioral Scales (NNNS) was also performed before and after NAS treatment. Changes in DNAm (DNAmpost-tx - DNAmpre-tx) and NNNS summary scores (NNNSpost-tx - NNNSpre-tx) were then calculated. Path analysis was used to examine associations among pharmacologic treatment (length of treatment [LOT] and total dose of morphine), changes in DNAm, and changes in NNNS summary scores.Results: DNAm was significantly decreased from pretreatment to post-treatment at 1 of 4 CpG sites within the OPRM1 gene. Neonates also demonstrated decreased excitability, hypertonia, lethargy, signs of stress and abstinence, and increased quality of movement and regulation from pretreatment to post-treatment. Longer LOT and higher morphine dose were associated with greater decreases in DNAm; greater decreases in DNAm were associated with greater decreases in excitability and hypertonia on the NNNS.Conclusions: Pharmacologic treatment of NAS is associated with decreased DNAm of the OPRM1 gene and improved neonatal neurobehavior. Epigenetic changes may play a role in these changes in neonatal neurobehavior. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|